Propranolol for Infantile Hemangiomas: Early Experience at a Tertiary Vascular Anomalies Center

被引:131
|
作者
Buckmiller, Lisa M. [1 ]
Munson, Patrick D. [1 ]
Dyamenahalli, Umesh [2 ]
Dai, Yuemeng [1 ]
Richter, Gresham T. [1 ]
机构
[1] Univ Arkansas Med Sci, Arkansas Childrens Hosp, Dept Otolaryngol, Div Pediat Otolaryngol, Little Rock, AR 72202 USA
[2] Univ Arkansas Med Sci, Arkansas Childrens Hosp, Dept Pediat, Little Rock, AR 72202 USA
来源
LARYNGOSCOPE | 2010年 / 120卷 / 04期
关键词
Propranolol; hemangioma; birthmark; beta-blocker; CLASSIFICATION; VINCRISTINE; CHILDREN; INFANCY;
D O I
10.1002/lary.20807
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Objectives/Hypothesis: Propranolol has recently been introduced as a novel pharmacologic treatment for infantile hemangiomas Systematic examination of this treatment in a tertiary care setting has not been described This study explores the impact of propranolol on both proliferative and involuting hemangiomas at a tertiary vascular anomalies center. Study Design: Retrospective single institution review Materials and Methods: We reviewed children treated with propranolol for problematic hemangiomas followed by a blinded prospective analysis of serial photographs taken during the course of their therapy Parental questionnaires were obtained to evaluate perceived therapeutic response and complications to oral propranolol. Results: Thirty-two children with complete photo documentation were treated with oral propranolol for infantile hemangiomas between September 2008 and June 2009 Twenty-seven patients began therapy during the proliferative phase of their lesions (mean age, 4 9 months), whereas five patients began during the involutional phase (mean age, 19.4 months) Ninety-seven percent of patients displayed improvement in the quality of their hemangiomas during propranolol therapy Patients were determined to be excellent responders (n = 16, 50%), partial responders (n = 15, 47%), or nonresponders (n = 1, 3%) Partial and nonresponders received adjuvant therapy (75%, laser therapy; 31%, steroid injections). Ten patients experienced minor but reportable side effects to propranolol, including somnolence (27.2%), gastroesophageal reflux (9.1%), respiratory syncytial virus exacerbation (4.5%), and rash (4.5%). Conclusions: Propranolol may revolutionize the treatment of problematic hemangiomas that cause imminent functional or cosmetic sequelae. At therapeutic doses, propranolol is safe and effective in the majority of patients. Adjunctive therapies may still be required Minor side effects, expected from beta-blocker therapy, are common but easily managed.
引用
收藏
页码:676 / 681
页数:6
相关论文
共 50 条
  • [31] Topical Propranolol Therapy for Infantile Hemangiomas
    Kunzi-Rapp, Karin
    PEDIATRIC DERMATOLOGY, 2012, 29 (02) : 154 - 159
  • [32] Therapeutic efficacy of propranolol for infantile hemangiomas
    Wu, Wenli
    Wang, Hongtao
    Hao, Jiansuo
    Gao, Zijun
    Li, Fan
    Chen, Yiyang
    ORAL SURGERY ORAL MEDICINE ORAL PATHOLOGY ORAL RADIOLOGY, 2019, 128 (02): : 132 - 138
  • [33] Propranolol for the Treatment of Orbital Infantile Hemangiomas
    Fridman, Gretta
    Grieser, Eric
    Hill, Robert
    Khuddus, Nausheen
    Bersani, Tom
    Slonim, Charles
    OPHTHALMIC PLASTIC AND RECONSTRUCTIVE SURGERY, 2011, 27 (03): : 190 - 194
  • [34] Propranolol as Diagnostic Tool for Infantile Hemangiomas
    Theunissen, Carla I. J. M.
    van der Horst, Chantal M. A. M.
    JOURNAL OF CRANIOFACIAL SURGERY, 2013, 24 (06) : 2218 - 2218
  • [35] Propranolol for Infantile Hemangiomas: Strawberry Matters?
    Kam Lun Ellis Hon
    Andrew Burd
    Winnie C. Chu
    Vincent Lee
    Chi Kong Li
    The Indian Journal of Pediatrics, 2012, 79 : 130 - 131
  • [36] Failure of Intralesional Propranolol in Infantile Hemangiomas
    Torres-Pradilla, Mauricio
    Baselga, Eulalia
    PEDIATRIC DERMATOLOGY, 2014, 31 (02) : 156 - 158
  • [37] Propranolol for infantile hemangiomas with hyperinsulinemic hypoglycemia
    Miyazaki, Taichi
    Ozeki, Michio
    Sasai, Hideo
    Ohnishi, Hidenori
    PEDIATRICS INTERNATIONAL, 2021, 63 (06) : 724 - 725
  • [38] Propranolol for Infantile Hemangiomas: Strawberry Matters?
    Hon, Kam Lun Ellis
    Burd, Andrew
    Chu, Winnie C.
    Lee, Vincent
    Li, Chi Kong
    INDIAN JOURNAL OF PEDIATRICS, 2012, 79 (01): : 130 - 131
  • [39] Propranolol for treatment of ulcerated infantile hemangiomas
    Saint-Jean, Melanie
    Leaute-Labreze, Christine
    Mazereeuw-Hautier, Juliette
    Bodak, Nathalie
    Hamel-Teillac, Dominique
    Kupfer-Bessaguet, Ingrid
    Lacour, Jean-Philippe
    Naouri, Michael
    Vabres, Pierre
    Hadj-Rabia, Smail
    Nguyen, Jean-Michel
    Stalder, Jean-Francois
    Barbarot, Sebastien
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2011, 64 (05) : 827 - 832
  • [40] Propranolol cellular targets in infantile hemangiomas
    Prey, S.
    Andre, M. Cario
    Pain, C.
    Leaute-Labreze, C.
    Taieb, A.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2013, 133 : S184 - S184